Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645951 | 0.82 | RXRB (0.36) | RXRB | |
| SCHEMBL27952594 | 0.79 | RXRB (0.36) | RXRB | |
| SCHEMBL14142238 | 0.75 | TDO2 (0.32) | TDO2AKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL21381466 | 0.72 | TSHR (0.40) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL28198733 | 0.71 | RXRB (0.35) | RXRB | |
| SCHEMBL28860851 | 0.71 | RXRB (0.35) | RXRB | |
| SCHEMBL28491055 | 0.70 | — | — | |
| SCHEMBL14645939 | 0.70 | TDO2 (0.31) | TDO2AKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL18772556 | 0.70 | AKR1C3 (0.30) | AKR1C3AKR1C2CNR1CNR2NR1I2 | |
| SCHEMBL14645582 | 0.69 | KDM4E (0.33) | RXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2746301-B1 | Catalyst | BOREALIS AG (AT) | 2018-05-30 | — | — | EP | disclosed |
| US-9598517-B2 | Catalysts | BOREALIS AG (AT) | 2017-03-21 | — | — | US | disclosed |
| US-20150344596-A1 | CATALYSTS | BOREALIS AG (AT) | 2015-12-03 | — | — | US | disclosed |
| EP-2746301-A1 | Catalyst | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344596-A1 | CATALYSTS | SFN, AP3S1, H1-2 | TDO2 1206/4885AKR1C3 310/4885AKR1C2 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.